The Role of Community Pharmacy in Post-Discharge Warfarin Management

Leanne Stafford

BPharm(Hons)(Curtin) MPS MSHP

Submitted in fulfilment of the requirements for the Degree of Doctor of Philosophy

University of Tasmania

School of Pharmacy

January 2012
DECLARATION OF ORIGINALITY

This thesis contains no material which has been accepted for a degree or diploma by the University or any other institution, except by way of background information and duly acknowledged in the thesis, and to the best of my knowledge and belief no material previously published or written by another person except where due acknowledgement is made in the text of the thesis, nor does the thesis contain any material that infringes copyright.

Leanne Stafford

19 January 2012
STATEMENT OF AUTHORITY OF ACCESS

This thesis may be made available for loan and limited copying in accordance with the Copyright Act of 1968.

Leanne Stafford

19 January 2012
STATEMENT OF ETHICAL CONDUCT

The research associated with this thesis abides by the international and Australian codes on human and animal experimentation, the guidelines by the Australian Government's Office of the Gene Technology Regulator and the rulings of the Safety, Ethics and Institutional Biosafety Committees of the University.

All research procedures reported in the thesis were approved by the Tasmania Health and Medical Human Research Ethics Committee or the Tasmanian Social Sciences Human Research Ethics Committee.

Leanne Stafford

19 January 2012
ABSTRACT

Warfarin is the most widely prescribed oral anticoagulant worldwide and a major contributor to drug-related morbidity and mortality. Many of the clinical and healthcare system-related problems encountered during routine warfarin management are amplified in the period following a patient’s discharge from hospital, further increasing the risk of adverse outcomes. Hospital-based post-discharge warfarin management services are limited in their capacity to manage all of the patients in need of care, and there is significant geographic variation in their availability. It has been demonstrated that pharmacists can successfully adopt a variety of roles in warfarin management; making greater use of their skills may contribute to reductions in the rates of warfarin-related adverse events in the post-discharge period.

A previous study conducted by Jackson et al. in southern Tasmania demonstrated the potential of a pharmacist-delivered, home-based post-discharge warfarin management service to improve the initiation of warfarin therapy and significantly decrease the rates of total bleeding, major bleeding and minor bleeding complications in the first three months post-discharge. Patient feedback was highly positive, and a cost-analysis estimated that widespread implementation of the service would lead to $A5 million per annum in overall cost savings to the healthcare system. While this program was highly successful, it was believed that the intensity of the four-visit model may not prove sustainable for wide scale implementation.

The objective of this study was to develop and implement a sustainable pharmacist-delivered post-discharge warfarin management service to enable the smooth transition of both newly anticoagulated patients and those already taking warfarin from the hospital to community setting. Patients received either two or three home visits in their eight to ten days post-discharge, with point-of-care (POC) International Normalised Ratio (INR) monitoring and warfarin education integrated into the existing Australian government-funded Home Medicines Review (HMR) program in an attempt to assure its sustainability. The
service was investigated in a prospective, non-randomised controlled cohort study. Evaluation of the service included assessment of its clinical and educational outcomes, a formal economic analysis and a qualitative study of stakeholder satisfaction focusing strongly on the logistical aspects of service implementation and delivery.

Patients were recruited from eight hospital sites in five major centres across three Australian states. One hundred and thirty-nine patients received standard management by their general practitioner (GP) (‘usual care’) and 129 received the post-discharge service. The service was associated with statistically significantly reductions in the rates of combined major and minor bleeding events (5.3% vs. 14.7%, p=0.03) and combined bleeding and thromboembolic events (6.4% vs. 19.0%, p=0.008) to Day 90 post-discharge. Persistence with therapy, based on the proportion of patients continuing warfarin at Day 90, improved from 83.6% to 95.4% (p=0.004); an improvement in warfarin knowledge was also demonstrated. No significant differences in self-reported adherence, quality of life, hospital readmission and death rates or INR control were observed. The cost-analysis demonstrated that the costs to the healthcare system of providing the service were greatly exceeded by reductions in the costs of warfarin-related hospital admissions; the service was therefore shown to be highly cost-effective in regards to warfarin-related costs. An uncertainty analysis indicated that it was cost dominant in approximately 80% of the iterations of the model, and business cases suggested that it was a viable prospect from the perspectives of both the Australian government and the community pharmacy sector.

The qualitative study identified that the service was popular with patients and some elements, such as the warfarin education, were universally recognised as beneficial. Major barriers were perceived to the implementation of the service via the HMR program, however, especially with respect to the existing referral process. Issues were highlighted regarding GP and community pharmacy engagement with the service, and the need for improved information technology solutions was recognised to promote effective communication between
multidisciplinary care providers. Pharmacist workload and remuneration were also identified as potentially problematic. As a result of these issues, stakeholders considered the current service model largely unviable, promoting instead a range of alternative service models.

In conclusion, this study demonstrated undeniable deficiencies in current community-based post-discharge warfarin management practices and positive outcomes arising from the post-discharge service. It failed, however, to produce sufficient evidence to support its widespread implementation in its current form. The optimal method of delivering clinical pharmacy services in the community remains uncertain, and new paradigms may need to be explored as anticoagulation management practices continue to evolve into the future.
ACKNOWLEDGMENTS

This study was primarily funded by the Australian Government Department of Health and Ageing as part of the Fourth Community Pharmacy Agreement through the Fourth Community Pharmacy Agreement Grants Program, managed by the Pharmacy Guild of Australia (PGA).

I would like to sincerely thank everyone who contributed their time and effort to the successful completion of the study. In particular, I would like to acknowledge the members of the PGA Project Team for the vision and dedication that made this study a reality:

- Professor Gregory Peterson
- Dr Shane Jackson
- Dr Luke Bereznicki
- Professor Andrew McLachlan
- Dr Beata Bajorek
- Dr Manya Angley
- Dr Judy Mullan
- Luigi Gaetani
- Associate Professor Gary Misan
- Kimbra Fitzmaurice
- Ella van Tienen
- Geoff Hill
- Qualitative Researcher: Ian DeBoos
- Consultant Health Economists: Associate Professor Chris Doran, Thameemul Ansari Bin Jainullabudeen

The intellectual input and support of Professor Mark Nelson, Dr Katherine Marsden, Dr Pauline Warburton, Vaughn Eaton, Dr Sepehr Shakib, Dr John Maddison, Associate Professor Chris Doecke, Associate Professor Arduino Mangoni, Professor Wilf Yeo, Professor Jan Potter and Suzette Seaton is also acknowledged.

I would also like to thank:
• the PGA Advisory Panel, for their valuable insights and constructive criticism,

• the Project Advisory Group, for their time and effort in attending regular teleconferences and providing helpful input at crucial times: Ellen Maxwell (Royal College of Pathologists of Australia), Mary Collins (General Practice South), Peter Guthrey (PGA), Jessica Toleman (Society of Hospital Pharmacists of Australia), Veena Vather (National Stroke Foundation), Bill Kelly (Australian Association of Consultant Pharmacy), Associate Professor Janet Vial (Australian Medical Association) and Dr Peter Pohlner (Prince Charles Hospital),

• the presenters at the Information Evenings: Dr David Jupe, Associate Professor Alhossain Khalafallah, Professor Andrew McLachlan, Professor Wilf Yeo and Dr Sepehr Shakib,

• Dr David Jupe, Dr Ellen Maxwell and Associate Professor Janet Vial for their assistance in the development of Module 3 of the Anticoagulation Education Program,

• Ros Bonar (RACP Quality Assurance Program), for her assistance in the development of the quality control plan for the CoaguChek® XS monitors,

• the enthusiastic, dedicated and sometimes long-suffering project officers, without whose efforts none of this would have been possible:
  
  o Tasmania: Geoff Hill, Lisa Ho, Josie Hughes, Tonie Miller, Marion Saltmarsh, Mackenzie Williams
  
  o NSW: Lou Gaetani, Judy Arnott, Judy Oliver, Kaajal Prasad
  
  o SA: Margaret Davey, Nicola Hughes, Louise Sheridan, Liz Learnihan, Christopher Thompson,

• Peter Gee, Glenn Hadolt, Dr Ivan Bindoff and Andrew Stafford, for their computing expertise at crucial times,
- a large number of hospital staff across all the sites for their assistance in recruitment, organising access to INR results, obtaining information regarding readmissions and clinical coding data, and a myriad of other tasks, and

- all study participants - patients, GPs, community and accredited pharmacists.

On a more personal note, there are a few people who deserve special recognition for their various contributions to my PhD research. I would especially like to thank my supervisors, Professor Gregory Peterson and Dr Luke Bereznicki, for recruiting me to the Unit for Medication Outcomes Research and Education (UMORE) ‘on faith’ and providing me with the opportunity to embark on a PhD that had eluded me previously, for their inspirational examples as researchers and practitioners, and for their ‘delicate’ supervision that has always left me feeling well-supported but has acknowledged my abilities and allowed me to work with significant autonomy.

One of the highlights of my research journey has been meeting people who have become not only valued collaborators and colleagues, but also friends - Dr Manya Angley and Dr Judy Mullan fall into this category. I would also like to thank my brother, Andrew Stafford, whose own PhD journey led me to UTAS and who has shared so many of the highs and lows with me; and my officemates, Ella van Tienen (nee Jeffrey) and Corinne Mirkazemi, for their support in times of (sometimes mutual) PhD-related angst. From the beginning, I have owed so much to my parents, Ken and Lesley Stafford, who gave me the freedom to choose this direction even though it led me far from home, and constantly offered their loving support from afar. Finally, all the thanks and love in the world go to my husband, Ben Chalmers, who appeared in my life in the midst of it all and whose warm heart and loving soul have provided me with the strength to achieve what seemed at times impossible.

Thank you.
PUBLICATIONS

All publications listed resulted from work described in this thesis.

Peer-reviewed Journal Publications


Government-Commissioned Report


Letters to the Editor


Conference Abstracts


- Stafford L, Peterson L, Bereznicki L, Jeffrey E, Jackson S. Early outcomes of a pharmacist-led post-discharge warfarin management service. Conference


PRIZES


TABLE OF CONTENTS

DECLARATION OF ORIGINALITY .......................................................... II
STATEMENT OF AUTHORITY OF ACCESS ........................................... III
STATEMENT OF ETHICAL CONDUCT ................................................... IV
ABSTRACT ......................................................................................... V
ACKNOWLEDGMENTS ..................................................................... VIII
PUBLICATIONS .................................................................................. XI
PRIZES .............................................................................................. XV
TABLE OF CONTENTS ........................................................................ XVI
LIST OF TABLES ................................................................................ XXIII
LIST OF FIGURES .............................................................................. XXVIII
LIST OF APPENDICES ....................................................................... XXX
ABBREVIATIONS ............................................................................. XXXI
CHAPTER ONE ................................................................................... 1

1. BACKGROUND AND LITERATURE REVIEW ......................... 1
   1.1. Warfarin Therapy ............................................................... 1
   1.2. Mechanism of Action ....................................................... 1
       1.2.1 Anticoagulant Effect .................................................. 1
       1.2.2 Procoagulant Effect .................................................. 3
   1.3. Pharmacokinetics ............................................................. 3
   1.4. Clinical Indications ........................................................... 4
       1.4.1 Venous Thromboembolism ...................................... 6
       1.4.2 Atrial Fibrillation ....................................................... 7
       1.4.3 Heart Valve Replacement ......................................... 10
   1.5. Warfarin Dosing and Monitoring .................................... 11
       1.5.1 The International Normalised Ratio (INR) ................. 11
           1.5.1.1 Pathology INR Monitoring ............................... 12
           1.5.1.2 Point-of-Care INR Monitoring ....................... 13
           1.5.1.2.1 Patient Self-Monitoring and Self-Management 15
       1.5.2 Warfarin Initiation ..................................................... 16
   1.5.3 Monitoring Maintenance Therapy ................................ 17
   1.6. Adverse Effects ................................................................. 18
       1.6.1 Bleeding ................................................................. 18
           1.6.1.1 Treatment-Related Factors Influencing Bleeding Risk 19
           1.6.1.2 Patient-Related Factors Influencing Bleeding Risk 21
           1.6.1.2.1 Age ............................................................ 21
           1.6.1.2.2 Genetic Factors ........................................... 22


1.6.1.2.3. Other Factors ......................................................... 24

1.6.1.3. Bleeding Risk Scores .................................................. 24

1.6.1.4. Warfarin Reversal .................................................. 26

1.6.2 Other Adverse Effects .................................................. 27

1.7. Drug Interactions ......................................................... 28

1.7.1 Pharmacokinetic Interactions ..................................... 28

1.7.2 Pharmacodynamic Interactions ................................ 28

1.8. Influence of Diet and Alcohol Intake ................................ 31

1.9. Barriers to Successful Anticoagulation .......................... 31

1.9.1 Warfarin-Related Adverse Events .............................. 31

1.9.2 Logistics of Warfarin Management .............................. 33

1.9.3 Patient Education and Knowledge .............................. 33

1.9.4 Non-Adherence .......................................................... 36

1.9.5 INR Control ............................................................... 37

1.9.6 Underutilisation ......................................................... 39

1.10. Warfarin Management in the Post-Discharge Period ...... 42

1.10.1 Existing Australian Post-Discharge Services .............. 45

1.10.2 Other Post-Discharge Services .................................. 46

1.10.2.1. Post-Discharge Warfarin Management Services ... 49

1.10.3 The Pharmacist’s Role in Warfarin Management ......... 53

1.10.3.1. Pharmacist-Led Home-Based Warfarin Management .. 55

1.10.4 Qualitative Analysis of Post-Discharge Warfarin Management ...... 57

1.10.4.1. Major Themes ...................................................... 58

1.10.4.1.1. Theme: Appropriate Warfarin Education is Integral to Effective Warfarin Management ......................................................... 58

1.10.4.1.2. Theme: Problems Occur in Communication along the Continuum of Care .......................................................... 60

1.10.4.1.3. Theme: Home-Delivered Services are Valuable to Both Patients and Healthcare Professionals ......................................................... 62

1.10.4.2. Facilitators of, and Barriers to, a New Service ........ 62

1.10.4.2.1. Facilitators .......................................................... 62

1.10.4.2.2. Barriers ............................................................ 66

1.10.4.3. Major Findings ...................................................... 69

1.11. Justification for the Current Study .............................. 71

1.12. Objectives ................................................................. 71

1.12.1 Hypotheses ............................................................. 71

CHAPTER TWO ........................................................................ 73

2. METHODOLOGY .......................................................... 73

2.1. Integration of Evidence Regarding Best Practice into the Service Model ....... 74

2.2. Pre-Study Planning ....................................................... 76
CHAPTER FOUR

4. QUALITATIVE STUDY OF STAKEHOLDER SATISFACTION

4.1. Introduction and Objectives

4.2. Methodology

4.2.1. Participant Recruitment

4.2.2. Data Collection

4.2.3. Data Analysis

4.3. Results

4.3.1. Participant Characteristics

4.3.2. Participants’ Experience of ‘Usual Care’
4.3.3 Response to the Service ................................................................. 178
   4.3.3.1. Consumers were Very Happy with the Service .................. 178
   4.3.3.2. GPs’ Responses were More Variable ............................ 180
   4.3.3.3. Accredited Pharmacists Responses Varied Between States .... 183
   4.3.3.4. Community Pharmacists Felt Disengaged from the Process  184
4.3.4 Elements of the Service ............................................................. 185
   4.3.4.1. Warfarin Education was Well-Received by All .................. 185
   4.3.4.2. Home Visits were Convenient and Assisted Education ......... 187
   4.3.4.3. POC INR Monitoring Polarised the Participants ................. 188
   4.3.4.4. The HMR Received Variable Responses ............................ 193
   4.3.4.5. Communication Proved Problematic in Some Situations ...... 196
      4.3.4.5.1. Improvements to the Communication Processes .......... 201
   4.3.4.6. Visit Frequency, Timing and Content Provoked Much Discussion 202
   4.3.4.7. The Service May Have Had an Effect on GP Visits ............... 204
4.3.5 Drivers and Barriers ................................................................. 206
   4.3.5.1. Patient Pressure Would Determine Service Uptake .......... 207
      4.3.5.1.1. Patients Should be Appropriately Selected for the Service .... 207
   4.3.5.2. A High Quality Service and Good Patient Outcomes Will Convince GPs 212
   4.3.5.3. Stakeholder Promotion and Engagement is Required for Service Awareness .... 214
   4.3.5.4. Workload and Remuneration Issues May Prove to Be Major Barriers ...... 216
   4.3.5.5. Community Pharmacy Involvement Needs Review ............. 222
   4.3.5.6. Alternative Service Models Could be Considered ............... 225
4.4 Discussion ................................................................................. 229
   4.4.1 Overall Response to the Service ............................................. 229
   4.4.2 Perceptions of the Various Aspects of the Service .................. 230
   4.4.3 Drivers and Barriers to Wider Implementation of the Service .... 231
   4.4.4 Limitations ..................................................................... 232
CHAPTER FIVE ................................................................................. 234
5. ECONOMIC ANALYSIS ................................................................. 234
   5.1. Introduction .................................................................. 234
   5.2. Objectives .................................................................... 235
   5.3. Methods ....................................................................... 236
      5.3.1. Estimation of Costs and Consequences ....................... 237
         5.3.1.1. Use of Medicare Australia Data ............................ 242
      5.3.2. Timeframe ............................................................. 245
      5.3.3. Uncertainty Analysis .................................................. 246
         5.3.3.1. Modelling of Event Rates ............................... 246
         5.3.3.2. Modelling of Costs ....................................... 247
   5.4. Results ...................................................................... 248
5.4.1 Cost-Analysis ............................................................................................................. 248
  5.4.1.1. Extrapolation to the Australian Population .................................................. 250
  5.4.1.2. Re-analysis Using Medicare Data .................................................................. 251
  5.4.1.3. Sensitivity Analysis ......................................................................................... 255
5.4.2 Cost-Effectiveness Analysis ...................................................................................... 256
5.4.3 Uncertainty Analysis .................................................................................................. 258
5.5. Business Case for Community Pharmacy for the Provision of the Post-Discharge Warfarin Management Service ....................................................................... 259
  5.5.1 Question 1. Is the provision of this service via community pharmacy cost-effective? .......................................................................................................................... 260
  5.5.2 Question 2. What is the cost to community pharmacy for setting up this service? ................................................................................................................................. 260
  5.5.3 Question 3. What is the cost to community pharmacy for providing this service? ................................................................................................................................. 264
  5.5.4 Question 4. How much is the patient willing to pay for this service? .................. 266
  5.5.5 Question 5. Who should pay for this service and how should the service be financed? .......................................................................................................................... 267
  5.6.1 Question 1. Is the provision of this service via community pharmacy cost-effective? ................................................................................................................................. 269
  5.6.2 Question 2. What is the cost to the Government for setting up this service? ........ 270
  5.6.3 Question 3. What is the cost to the Government for supporting ongoing provision of these services? ............................................................................................................. 272
  5.6.4 Question 4. How much is the patient willing to pay for this service? .................. 273
  5.6.5 Question 5. Who should pay for this service and how should the service be financed? .......................................................................................................................... 273

CHAPTER SIX ............................................................................................................................. 277
6. DISCUSSION AND RECOMMENDATIONS ....................................................................... 277
  6.1. Evidence Base of the Service Model ........................................................................... 277
  6.2. Outcomes of the Service ............................................................................................. 278
    6.2.1 Clinical Outcomes ................................................................................................. 278
      6.2.1.1. Bleeding Events ............................................................................................ 280
    6.2.2 Warfarin Knowledge ............................................................................................. 284
    6.2.3 Adherence and Persistence ................................................................................... 286
    6.2.4 Quality of Life ....................................................................................................... 288
    6.2.5 Recommendations in the Home Medicines Reviews .......................................... 289
  6.3. Implementation Issues: Barriers and Facilitators ....................................................... 293
    6.3.1 Accredited Pharmacist Training .......................................................................... 293
    6.3.2 Integration of the Service into the Home Medicines Review Program ............... 298

xxi